September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Repeated Dexamethasone Implants in Patients with Refractory Macular Edema Receiving Anti-VEGF Therapy
Author Affiliations & Notes
  • Betsy Colon
    Retina, Associates in Ophthalmology, Pittsburgh, Pennsylvania, United States
  • Miguel Busquets
    Retina, Associates in Ophthalmology, Pittsburgh, Pennsylvania, United States
  • Pomykala Matthew
    Retina, Associates in Ophthalmology, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Betsy Colon, None; Miguel Busquets, None; Pomykala Matthew , None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4149. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Betsy Colon, Miguel Busquets, Pomykala Matthew; Repeated Dexamethasone Implants in Patients with Refractory Macular Edema Receiving Anti-VEGF Therapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4149.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aim of this study is to present the clinical outcomes of patients with macular edema treated with repeated Dexamethasone 0.7 mg (DEX) implants after failure with Anti-vascular endothelial growth factor (anti-VEGF) therapy.

Methods : Patients (n=5) from an ophthalmology clinic consecutively treated with DEX implants for macular edema (ME) from all etiologies were retrospectively evaluated. Demographic data, LogMar and Snellen visual acuity (VA) and central macular thickness (CMT) calculated by spectral domain optical coherence tomography (SDO-OCT) were subjected to statistical analysis.

Results : A total of 6 eyes with an average age of 67 years of age with a mean follow up period of of 78 weeks. Sixty-six percent were diagnosed with central retinal vein occlusion (RVO), while the other 33% were with posterior uveitis. A mean of 5 anti-VEGF injections were administered before initiating DEX implant therapy. While in the anti-VEGF therapy phase mean VA worsened while CMT increased. Mean respective values were 0.84 +/- 0.36 LogMar scale (20/139 +/- 20/45) and 562 +/-261 at intervention of anti-VEGF therapy; while in the DEX implants therapy mean VA was 0.40 +/- 0.32 LogMar scale (20/50 +/- 20/45) and CMT 381 +/-118.

Conclusions : This study shows that the used of consecutive DEX implants is safe and effective, specially for refractory macular edema previously treated with anti-VEGF therapy.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×